666

MERCURY BIOPHARMACEUTICAL CORPORATI

No trades
See on Supercharts

6932 fundamentals

An in-depth look to MERCURY BIOPHARMACEUTICAL CORPORATI operating, investing, and financing activities

6932 free cash flow for H1 24 is -15.18 M TWD. For 2023, 6932 free cash flow was -55.07 M TWD and operating cash flow was -42.15 M TWD.

‪0.00‬
Cash from operating activities
Cash from investing activities
Cash from financing activities
Currency: TWD
TTM
Free cash flowYoY growth